{"id":516660,"date":"2026-01-15T00:12:19","date_gmt":"2026-01-15T00:12:19","guid":{"rendered":"https:\/\/www.europesays.com\/us\/516660\/"},"modified":"2026-01-15T00:12:19","modified_gmt":"2026-01-15T00:12:19","slug":"secretive-project-prometheus-takes-vc-bob-nelsen-beyond-just-health-care","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/us\/516660\/","title":{"rendered":"Secretive Project Prometheus takes VC Bob Nelsen beyond just health care"},"content":{"rendered":"<p class=\"author-bio\">Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, <a href=\"https:\/\/www.statnews.com\/category\/readout-loud\/\" target=\"_blank\" rel=\"noopener\">The Readout Loud<\/a>.  You can reach Allison on Signal at AllisonDeAngelis.01.<\/p>\n<p>SAN FRANCISCO \u2014 Venture capitalist Bob Nelsen believes his latest project will be \u201cone of the most important companies in the world.\u201d But, unusually for the longtime biotech investor, it\u2019s not strictly in health care.<\/p>\n<p>Nelsen has been quietly working on a new artificial intelligence company called Project Prometheus alongside Amazon founder Jeff Bezos and Vik Bajaj, the former head of Foresite Capital\u2019s AI and science group, Foresite Labs. Bezos and Bajaj are serving as co-CEOs of Project Prometheus, according to The New York Times. Lauded scientist Rick Klausner is also part of the venture.\u00a0<\/p>\n<p>Few details of the venture have been revealed publicly, and its exact plans remain murky. According to Nelsen, Project Prometheus is melding AI with physics. \u201cIt\u2019s the challenge of figuring out how to reinvent the physical world. It\u2019s a big challenge,\u201d he said during a <a href=\"https:\/\/www.statnews.com\/2026\/01\/14\/readout-loud-podcast-jpm-2026-bob-nelsen-mike-doustdar\/\" target=\"_blank\" rel=\"noopener\">live taping of \u201cThe Readout LOUD,\u201d<\/a> STAT\u2019s weekly biotech podcast.\u00a0<\/p>\n<p class=\"restricted-text\">STAT+ Exclusive Story<\/p>\n<p class=\"restricted-login\">Already have an account? <a href=\"https:\/\/www.statnews.com\/login\/\" data-stat-login=\"\" data-stat-paywall-cta=\"breaker login cta\" target=\"_blank\" rel=\"noopener\">Log in<\/a><\/p>\n<p>\t\t\t<img decoding=\"async\" class=\"restricted-content-breaker-bg\" src=\"https:\/\/www.europesays.com\/us\/wp-content\/uploads\/2025\/06\/stat-plus-breaker-bg.png\" alt=\"STAT+\"\/><\/p>\n<p>\t\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" target=\"_blank\" rel=\"noopener\"><br \/>\n\t\t\t\t\t\t<img decoding=\"async\" class=\"stat-plus-logo\" src=\"https:\/\/www.statnews.com\/wp-content\/themes\/stat\/images\/stat-plus-logo-white.svg\" alt=\"STAT+\"\/><br \/>\n\t\t\t\t\t<\/a><\/p>\n<p>\t\t\t\tThis article is exclusive to STAT+ subscribers<br \/>\n\t\t\t\tUnlock this article \u2014 plus daily coverage and analysis of the biotech sector \u2014 by subscribing to STAT+.<\/p>\n<p class=\"restricted-content-breaker-wrapper-cta mobile\">Already have an account? <a href=\"https:\/\/www.statnews.com\/login\/\" data-stat-login=\"\" data-stat-paywall-cta=\"breaker login cta mobile\" target=\"_blank\" rel=\"noopener\">Log in<\/a><\/p>\n<p>\t\t\t\t\t\tIndividual plans<\/p>\n<p>\t\t\t\t\t\tGroup plans<\/p>\n<p>\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" class=\"stat-button view-all\" data-stat-paywall-cta=\"breaker view all plans\" aria-label=\"View All Plans\" target=\"_blank\" rel=\"noopener\">View All Plans<\/a><\/p>\n<p class=\"restricted-content-text\">\n\t\t\t\t\t\tTo read the rest of this story subscribe to STAT+.\t\t\t\t\t<\/p>\n<p>\t\t\t\t\t<a href=\"https:\/\/www.statnews.com\/stat-plus\/\" class=\"stat-button restricted-button\" data-stat-paywall-cta=\"breaker subscribe cta 1\" target=\"_blank\" rel=\"noopener\">Subscribe<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and&hellip;\n","protected":false},"author":3,"featured_media":516661,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[35],"tags":[738,150,210,1141,29387,1142,153059,154,67,132,68],"class_list":{"0":"post-516660","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-health-care","8":"tag-artificial-intelligence","9":"tag-biotechnology","10":"tag-health","11":"tag-health-care","12":"tag-health-tech","13":"tag-healthcare","14":"tag-jpm","15":"tag-stat","16":"tag-united-states","17":"tag-unitedstates","18":"tag-us"},"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@us\/115896224645771883","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/516660","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/comments?post=516660"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/posts\/516660\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media\/516661"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/media?parent=516660"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/categories?post=516660"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/us\/wp-json\/wp\/v2\/tags?post=516660"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}